Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of TAK-418 in Healthy Subjects
NCT03228433Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-418 in Kabuki syndrome and Autism Spectrum Disorder (ASD) (6 arms), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events at Day 184, Number of Participants Who Discontinued Due to an Adverse Event at Day 184 and 4 more. Started Jul 2017; status: completed.
02
Drugs
TAK-418
03
Conditions
Kabuki syndromeAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03228433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228433.